# Assessment of Drug-drug Interactions Between Feminizing Hormone Therapy and Emtricitabine/Tenofovir Alafenamide Concomitantly for Pre-exposure Prophylaxis Among Transgender Women

> **NCT04590417** · NA · ACTIVE_NOT_RECRUITING · sponsor: **Thai Red Cross AIDS Research Centre** · enrollment: 20 (actual)

## Conditions studied

- Drug Interaction

## Interventions

- **DRUG:** Estradiol valerate 2 mg, cyproterone acetate 25 mg

## Key facts

- **NCT ID:** NCT04590417
- **Lead sponsor:** Thai Red Cross AIDS Research Centre
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-01-24
- **Primary completion:** 2024-01-01
- **Final completion:** 2025-10-01
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2024-11-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04590417

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04590417, "Assessment of Drug-drug Interactions Between Feminizing Hormone Therapy and Emtricitabine/Tenofovir Alafenamide Concomitantly for Pre-exposure Prophylaxis Among Transgender Women". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04590417. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*